Macsen Labs Group announces the commencement of construction of its new Active Pharmaceutical Ingredient (API) manufacturing facility near one of its existing units, Macsen Drugs in RIICO Industrial Area, Gudli, Udaipur, Rajasthan, India. This strategic development represents a major advancement in their dedication to improving manufacturing capacities to meet the increasing demands of the pharmaceutical sector.
Spanning over an expansive area of 25,000 square meters, the new facility is five times larger in land area compared to the current infrastructure at Macsen Drugs, which is a USFDA inspected, TGA-GMP, and WHO-GMP certified manufacturing unit. Designed to support scalability and operational efficiency, the new facility will include multiple API production blocks capable of handling diverse and advanced manufacturing processes for APIs for various therapeutic applications.
Macsen plans to invest approximately INR 75 crore in the initial phase of development, which will include two multistorey API Production Blocks equipped with cutting-edge technology and a combined reactor capacity of 100 KL (both stainless steel & glass-lined reactors); a new dedicated state-of-the-art R&D center over an area of 15,000 sq ft; an advanced Pilot Plant equipped with comprehensive process equipment and technologies, which will enable pilot-scale production of APIs and commercial production of low-volume, pre-clinical and clinical trial APIs.
“We also have the plan to install a special production line for manufacturing & performing corrosive chemistries with Hastelloy, Halar-coated equipment, etc.,” said Mr. Achal Agrawal, Chairman and CEO of Macsen Group. He further stated, “We aim to commence production activities at this new facility by the end of 2025. This expansion underscores our long-term vision to strengthen our manufacturing footprint and enhance our capacity to deliver high-quality, cost-effective pharmaceutical solutions to the global market.”
